RRM2 and ductal breast carcinoma in situ: Our findings were validated by another study to some extent, and they found DEPDC1, EXO1, RRM2 and some proteins had enhanced expression in the ductal carcinoma in situ and invasive ductal carcinoma (Kretschmer et al., 2011).